The State of Asthma Care in the UK
The numbers paint a stark picture. Around three people die from an asthma attack every day in the UK, and the NHS spends roughly £1 billion annually treating and managing the condition. That is not just a statistic. It is the reality of a healthcare system that has effective treatments but still struggles to reach every patient who needs them.
Part of the challenge lies in how asthma presents itself. Not all asthma is the same. Some patients have what specialists call type 2 inflammation, driven by elevated eosinophils—a type of white blood cell that fuels airway swelling. For these individuals, standard inhalers, even at high doses, often fall short. Others battle with triggers that are hard to pin down, from pollen to stress to the common cold. The result is a cycle of flare-ups, steroid courses, and hospital visits that wears people down.
Against this backdrop, the UK has quietly become a hub for respiratory research. From the University of Oxford's respiratory medicine unit to the specialised severe asthma centres in Southampton, Belfast, and Glasgow, British researchers are running trials that range from early-stage proof-of-concept studies to large-scale registries tracking thousands of patients over years. The UK Severe Asthma Registry, for instance, has been instrumental in understanding how biological remission—where a patient's immune system stops attacking the airways—can become a realistic treatment target rather than wishful thinking.
What Types of Trials Are Happening Right Now
The landscape of asthma clinical trials in the UK has shifted dramatically in the past few years, largely driven by the arrival of biologic therapies. These are not the inhaled steroids of old. They are targeted treatments, often given by injection, that interrupt specific pathways in the inflammatory cascade.
One of the most significant recent developments is the UK approval of depemokimab (brand name Exdensur) by the Medicines and Healthcare products Regulatory Agency (MHRA). This is the first ultra-long-acting biologic for respiratory disease, requiring only two injections per year. It is approved for patients aged 12 and older with type 2 inflammation who remain uncontrolled despite maximum standard therapy. The trials behind this approval—named SWIFT and ANCHOR—showed sustained reductions in exacerbations and fewer hospitalisations. For patients who previously had to plan their lives around monthly clinic visits, a twice-yearly treatment represents a genuine shift in what is possible.
Another trial of note is the ABRA study, conducted at Oxford University Hospitals and other sites. This phase II trial compared benralizumab—another biologic targeting eosinophils—against standard prednisolone in patients presenting to emergency departments with acute asthma attacks. The question was simple but bold: could a single injection of a biologic do the job of a five-day steroid course? The results are still being analysed, but the very fact that researchers are asking this question reflects how far the field has moved.
Beyond biologics, there are trials exploring entirely different approaches. The IMP2ART programme is a cluster randomised controlled trial looking at how to embed improved asthma self-management into routine UK primary care. Rather than testing a new drug, it tests a new way of delivering care—training practice staff, using digital tools, and making sure patients have written action plans they actually understand and use. The internal pilot for this trial, published in early 2026, showed that the approach is feasible, and the full results could reshape how GPs across England, Scotland, Wales, and Northern Ireland support asthma patients.
A Quick Comparison of Trial Types
| Trial Type | What It Tests | Typical Duration | Who It Suits | Key Consideration |
|---|
| Biologic trials | New targeted injections (e.g., depemokimab, benralizumab) | 6–24 months | Severe, uncontrolled asthma with type 2 inflammation | Requires regular blood monitoring |
| Inhaler comparison studies | New formulations of existing medications | 3–12 months | Mild to moderate asthma | Often placebo-controlled |
| Self-management trials | Digital tools, action plans, practice-based interventions | 12–36 months | All asthma severities | May not involve new medication |
| Early-phase proof-of-concept | Novel mechanisms (e.g., bispecific antibodies) | 3–6 months | Usually severe asthma patients | Higher uncertainty, closer monitoring |
| Registry-based observational studies | Long-term outcomes of existing treatments | 5+ years | Patients already on treatment | No new intervention, just data collection |
Real Stories from the Trial Pathway
Carly Sylvester, a patient from Jersey, remembers her first asthma attack with unsettling clarity. She was seven years old, sleeping at a friend's house, unaware that the feather pillow beneath her head would trigger a reaction that sent her gasping down a hospital corridor. Over the next two decades, she cycled through inhalers, tablets, nebulisers, and steroid courses, each helping for a while but never enough.
Then specialists at Southampton General Hospital offered her mepolizumab, a biologic given as a monthly injection. The transformation was not subtle. Sylvester went from struggling through daily activities to completing the London Marathon, calling her quality of life "unbelievable." She is now a vocal advocate for the research that made her treatment possible. The new Institute for Medical Innovation (IMI) at Southampton, which focuses on respiratory disease among other areas, represents exactly the kind of infrastructure that turns laboratory discoveries into patient realities.
Her story is not unique, but it is also not universal. Access to biologics through the NHS depends on meeting strict eligibility criteria, typically involving blood eosinophil counts, exacerbation history, and confirmation that standard therapies have been exhausted. That is precisely why clinical trials matter—they are often the route through which patients can access cutting-edge treatments before they become widely available, while also contributing to the evidence base that decides what the NHS will fund in the future.
How to Find and Join a Trial
If you are considering participating in asthma research, the first step is simpler than most people assume. You do not need a referral from a consultant, though having one helps. The UK has several portals designed to connect patients with trials.
The Be Part of Research website, run by the National Institute for Health and Care Research (NIHR), aggregates clinical trials from multiple UK registers. You can search by condition, location, and trial phase, and in many cases you can contact the research team directly. For those who prefer a broader search, the World Health Organization's International Clinical Trials Registry Platform includes trials from around the world, though filtering by UK sites is straightforward.
Charities are another underused resource. Asthma + Lung UK maintains information about ongoing studies and can point you towards research that matches your specific situation. Their helpline staff are trained to discuss trial participation without pressuring anyone into a decision.
When you find a trial that looks relevant, the research team will guide you through an eligibility screening. This usually involves a medical history review, lung function tests, and blood work. You will receive a patient information sheet explaining the purpose of the study, what is involved, potential risks, and your right to withdraw at any time. Informed consent is not a one-time signature—it is an ongoing conversation throughout the trial.
What to Expect During Participation
Trial participation varies enormously depending on the study design. A biologic trial might require monthly clinic visits for injections and blood tests over a year or more. A self-management trial might involve just a few phone calls and some questionnaires. What is consistent across all reputable trials is the level of monitoring. You will likely have more frequent contact with healthcare professionals than you would during routine care, and any changes in your symptoms will be taken seriously.
One practical consideration is travel. While major trial centres are concentrated in cities like London, Manchester, Birmingham, Edinburgh, and Belfast, this can pose a challenge for patients in rural areas. Some trials reimburse travel expenses, and a growing number incorporate remote monitoring through apps and home spirometry devices. If geography is a barrier, ask the research team about these options before ruling yourself out.
There is also the question of placebo. In double-blind trials, neither you nor the research team knows whether you are receiving the active treatment or a placebo. This can feel unsettling, but it is the gold standard for determining whether a treatment actually works. Most trials that use a placebo also include what is called an "open-label extension" phase, where all participants eventually receive the active drug once the blinded part of the study is complete.
The Bigger Picture for UK Patients
The asthma research landscape in the UK is not static. The combination of a strong NHS infrastructure, world-class university research centres, and a regulatory environment that has shown itself willing to fast-track promising treatments—as seen with depemokimab's approval—means that patients here have opportunities that are not available everywhere.
For those living with asthma that disrupts sleep, work, and the simple act of walking upstairs, the question is not whether clinical trials are perfect. They are not. Some treatments fail. Some trials involve more time and travel than people can manage. But for a growing number of patients, the trial pathway has been the bridge between barely coping and genuinely living. The 5.4 million people managing asthma in the UK deserve every option that science can offer. If you are curious about what is available, start with the Be Part of Research website or speak to your GP or asthma nurse. The conversation itself costs nothing, and it might open a door you did not know existed.
研究の知恵